Schlesinger Naomi
a Department of Medicine Rutgers , Robert Wood Johnson Medical School , New Brunswick , NJ , USA.
Expert Opin Drug Saf. 2017 Apr;16(4):429-436. doi: 10.1080/14740338.2017.1284199. Epub 2017 Jan 30.
Gout is the most common inflammatory arthritis in humans. Gout treatment includes rapid initiation of anti-inflammatory medications for acute attacks and chronically treating with urate lowering drugs as well as chronic anti-inflammatory prophylaxis. Areas covered: This review aims to provide an overview and discussion of the safety concerns of current treatment options available for gout. Expert opinion: Gout is a curable disease with appropriate treatment. The advent of new therapies provides encouraging opportunities to improve gout management. However, clinicians should be aware of some of the safety concerns of medications used to treat acute and chronic gout. When prescribing medications for gout one has to be mindful of the presence of comorbidities commonly affecting gout patients that may affect drug safety and efficacy, especially in the elderly and in patients treated with multiple drugs. The benefits of gout drugs, usually, outweigh their safety concerns. Studies are needed in gout patients with chronic kidney disease and/or cardiovascular disease, so that escalation of dosing /combination of anti-inflammatory drugs needed to suppress gouty inflammation as well as escalation of dosing/combination of urate lowering drugs needed to achieve target serum urate level will lead to better understanding of gout treatment safety issues.
痛风是人类最常见的炎性关节炎。痛风治疗包括在急性发作时迅速启动抗炎药物治疗，以及使用降尿酸药物进行长期治疗和慢性抗炎预防。涵盖领域：本综述旨在概述和讨论目前痛风可用治疗方案的安全性问题。专家观点：痛风是一种可通过适当治疗治愈的疾病。新疗法的出现为改善痛风管理提供了令人鼓舞的机会。然而，临床医生应意识到用于治疗急性和慢性痛风的药物存在一些安全性问题。在为痛风患者开处方时，必须注意通常影响痛风患者的合并症的存在，这些合并症可能影响药物的安全性和疗效，尤其是在老年人和接受多种药物治疗的患者中。痛风药物的益处通常超过其安全性问题。需要对患有慢性肾病和/或心血管疾病的痛风患者进行研究，以便更好地理解抑制痛风性炎症所需的抗炎药物剂量增加/联合使用以及达到目标血清尿酸水平所需的降尿酸药物剂量增加/联合使用所带来的痛风治疗安全性问题。
